Valeant (VRX) Receives FTC Clearance to Acquire Medicis Pharma (MRX)
Tweet
Share
E-mail
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced today that the U.S. Federal Trade Commission (FTC) has completed its review of the proposed acquisition of Medicis Pharmaceutical Corporation (NYSE: MRX) by Valeant and has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) without conditions. The grant of early termination is effective as of November 15, 2012.
The proposed merger remains subject to other customary closing conditions, including the approval of the Medicis's stockholders at its special meeting of stockholders scheduled for December 7, 2012. The Company expects to close the merger within four business days following satisfaction of all closing conditions.
The proposed merger remains subject to other customary closing conditions, including the approval of the Medicis's stockholders at its special meeting of stockholders scheduled for December 7, 2012. The Company expects to close the merger within four business days following satisfaction of all closing conditions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Masonite Int'l (DOOR) Sells Architectural Business Segment
- E.W. Scripps Co. (SSP) exploring sale of Black-culture broadcast network Bounce TV - CNBC
- Hilton hikes 2024 earnings outlook as Q1 results beat expectations, shares up
Create E-mail Alert Related Categories
Corporate News, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
